Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Edwards Lifesciences Corp., consolidated income statement (quarterly data)

US$ in thousands

3 months ended:	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017
Net sales	1,329,700)	1,310,200)	1,376,000)	1,216,600)	1,191,700)	1,140,900)	925,000)	1,128,700)	1,174,100)	1,094,000)	1,086,900)	993,000)	977,700)	906,600)	943,700)	894,800)	888,500)	821,500)	841,800)	883,500)
Cost of sales	(309,500)	(311,700)	(334,300)	(293,400)	(296,300)	(281,000)	(238,200)	(265,100)	(286,200)	(292,400)	(304,000)	(231,800)	(234,700)	(224,900)	(246,200)	(233,600)	(235,300)	(213,300)	(211,100)	(215,600)
Gross profit	1,020,200)	998,500)	1,041,700)	923,200)	895,400)	859,900)	686,800)	863,600)	887,900)	801,600)	782,900)	761,200)	743,000)	681,700)	697,500)	661,200)	653,200)	608,200)	630,700)	667,900)
Selling, general, and administrative expenses	(424,000)	(364,400)	(374,500)	(330,800)	(338,500)	(307,200)	(274,900)	(307,800)	(347,200)	(306,200)	(308,500)	(280,300)	(288,100)	(269,500)	(274,900)	(256,000)	(266,700)	(244,600)	(243,800)	(229,600)
Research and development expenses	(232,800)	(238,000)	(225,300)	(207,000)	(195,700)	(195,500)	(182,100)	(187,400)	(193,900)	(195,500)	(191,900)	(171,400)	(163,100)	(161,800)	(154,100)	(143,200)	(146,600)	(142,900)	(134,400)	(128,700)
Intellectual property litigation income (expenses), net	(7,100)	(4,700)	(2,400)	(6,400)	(4,600)	(8,400)	(379,900)	(12,500)	(13,900)	(7,900)	(7,000)	(4,600)	(194,900)	(7,900)	(5,500)	(5,700)	104,900)	(13,700)	(7,700)	(10,200)
Change in fair value of contingent consideration liabilities	18,100)	(1,100)	102,600)	4,500)	(5,200)	9,000)	(19,600)	2,200)	18,500)	2,300)	(8,000)	(6,700)	14,000)	6,400)	(10,900)	(3,800)	(2,600)	16,700)	(3,100)	(1,100)
Special charges	—)	—)	—)	—)	—)	—)	—)	—)	(40,600)	—)	—)	(24,000)	(116,200)	—)	—)	—)	—)	(9,700)	—)	—)
Other operating expenses	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(700)	—)
Operating income (loss)	374,400)	390,300)	542,100)	383,500)	351,400)	357,800)	(169,700)	358,100)	310,800)	294,300)	267,500)	274,200)	(5,300)	248,900)	252,100)	252,500)	342,200)	214,000)	241,000)	298,300)
Interest income (expense), net	500)	(800)	(1,000)	300)	500)	800)	1,800)	4,500)	4,300)	2,800)	2,400)	2,000)	1,800)	(500)	—)	800)	1,000)	(100)	(1,400)	(2,400)
Special gains (charges), net	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	7,100)	(18,500)	(500)	(31,200)	—)
Other income (expense), net	1,400)	1,400)	4,400)	5,500)	4,200)	5,700)	(300)	1,900)	400)	4,600)	1,400)	1,800)	1,700)	300)	(1,100)	3,100)	(800)	(1,600)	(2,800)	(2,300)
Income (loss) before (provision for) benefit from income taxes	376,300)	390,900)	545,500)	389,300)	356,100)	364,300)	(168,200)	364,500)	315,500)	301,700)	271,300)	278,000)	(1,800)	248,700)	251,000)	263,500)	323,900)	211,800)	205,600)	293,600)
(Provision for) benefit from income taxes	(41,000)	(50,800)	(56,000)	(51,100)	(46,600)	(39,100)	46,300)	(53,900)	(35,300)	(27,000)	(29,000)	(28,300)	8,800)	(22,800)	31,700)	(56,900)	(326,700)	(41,700)	(19,500)	(63,400)
Net income (loss)	335,300)	340,100)	489,500)	338,200)	309,500)	325,200)	(121,900)	310,600)	280,200)	274,700)	242,300)	249,700)	7,000)	225,900)	282,700)	206,600)	(2,800)	170,100)	186,100)	230,200)

Download chart

Income statement item	Description	The company
Net sales	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	Edwards Lifesciences Corp. net sales decreased from Q2 2021 to Q3 2021 but then slightly increased from Q3 2021 to Q4 2021.
Operating income (loss)	The net result for the period of deducting operating expenses from operating revenues.	Edwards Lifesciences Corp. operating income (loss) decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Income (loss) before (provision for) benefit from income taxes	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Edwards Lifesciences Corp. income (loss) before (provision for) benefit from income taxes decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Net income (loss)	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Edwards Lifesciences Corp. net income (loss) decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.

Edwards Lifesciences Corp. (NYSE:EW)

Income Statement Quarterly Data

Income Statement
Quarterly Data